Positive results from phase 2 willow study of brensocatib in patients with non-cystic fibrosis bronchiectasis presented at ats virtual clinical trials session

Bridgewater, n.j., june 24, 2020 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that final results from the phase 2 willow study of brensocatib (formerly...
INSM Ratings Summary
INSM Quant Ranking